SENS

Senseonics is a genuine growth story wrapped around a severe funding problem. FY2025 revenue rose 56.9% to $35.3M and gross profit swung to $15.8M (44.7% gross margin, up from a near-zero base), validating that the implantable Eversense franchise — the 365-day Eversense 365 FDA-approved in Sep 2024, differentiated against the 7–15 day life of non-implantable CGMs, and reaching ~300M covered lives — is finding a market. The MD&A's key strategic shift reinforces the top-line case: effective January 2026 the company took over full U.S. commercial responsibility for Eversense 365 with its own sales force and now captures 100% of European Territory revenue after the Ascensia hand-back. Owning the commercial stack should lift revenue capture per unit.

But the numbers below the gross-profit line are alarming. The company lost $69.1M (net margin -196.0%, operating margin -193.8%) and burned $59.1M in operating cash against just $40.2M of cash and equivalents — cash already fell 46.1% year over year. That is well under a year of runway at the current burn, and taking commercial operations in-house will add sales/marketing cost precisely when the company can least afford it. The accumulated deficit is now -$1.02B. Most tellingly, the MD&A discloses a 1-for-20 reverse stock split effective October 2025 (the reason shares 'fell' 93.6% to 41.8M) — a classic listing-compliance and distress signal, not a value creation event.